Magenta Therapeutics, Inc. approved a restructuring plan (the Plan) to reduce the Company's operations to preserve financial resources, resulting in a reduction of the Company's workforce by up to 56 positions, or approximately 84%, to be substantially completed by February 17, 2023. In connection with the Plan, Jason Gardner, Chief Executive Officer will be leaving the Company to pursue new opportunities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.5 USD | +2.43% | -11.17% | +92.07% |
- Stock Market
- Equities
- MGTA Stock
- News Magenta Therapeutics
- Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer